Literature DB >> 11692175

Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals.

R M Fisher1, P Eriksson, J Hoffstedt, G S Hotamisligil, A Thörne, M Rydén, A Hamsten, P Arner.   

Abstract

AIMS/HYPOTHESIS: This study investigated the expression of adipose tissue fatty acid binding proteins (FABPs) in subcutaneous and visceral human adipose tissue depots from lean and obese individuals.
METHODS: Adipocyte lipid binding protein (ALBP) and keratinocyte lipid binding protein (KLBP) expression was quantified by western blot in subcutaneous and omental adipose tissue from 20 obese and 9 lean individuals. RNA expression was quantified by Northern blot in the obese subjects.
RESULTS: In the obese subjects, ALBP protein and RNA expression was higher in subcutaneous compared with omental adipose tissue (increases of 31 +/- 14 % and 40 +/- 13 % respectively, both p < 0.05), whereas in the lean group, KLBP protein levels were 32 +/- 9 % lower in subcutaneous fat (p < 0.03). However, the ALBP/KLBP ratio was greater in subcutaneous compared to omental adipose tissue from both lean and obese subjects: increases of 187 +/- 71 % (p = 0.01) and 52 +/- 23 % (p = 0.17) respectively for the protein ratio, and 21 +/- 6 % for RNA (p = 0.01, obese individuals). In lean subjects, insulin concentrations correlated positively with the ALBP/KLBP protein ratio in both depots (both p < or = 0.03). CONCLUSION/
INTERPRETATION: There are regional differences in adipose tissue FABP expression, which could be influenced by obesity. However, the ALBP/KLBP ratio is greater in subcutaneous than visceral adipose tissue in lean as well as in obese subjects. Investigation of adipose tissue FABPs could further our understanding of the role of fatty acids in the insulin resistance syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692175     DOI: 10.1007/s001250100643

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages.

Authors:  Sara L Coleman; Young-Ki Park; Ji-Young Lee
Journal:  Eur J Nutr       Date:  2010-11-03       Impact factor: 5.614

Review 2.  Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions.

Authors:  Nicholas P Hays; Pietro R Galassetti; Robert H Coker
Journal:  Pharmacol Ther       Date:  2008-03-02       Impact factor: 12.310

3.  Fatty acid binding protein expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals.

Authors:  R M Fisher; A Thörne; A Hamsten; P Arner
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

4.  A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.

Authors:  G Tuncman; E Erbay; X Hom; I De Vivo; H Campos; E B Rimm; G S Hotamisligil
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

Review 5.  Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Authors:  S Kralisch; M Fasshauer
Journal:  Diabetologia       Date:  2012-09-29       Impact factor: 10.122

6.  Circulating FABP4 and FABP5 levels are differently linked to OSA severity and treatment.

Authors:  Raquel Català; Anna Cabré; Salvador Hernández-Flix; Raimón Ferré; Sandra Sangenís; Núria Plana; Anna Texidó; Lluís Masana
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

7.  FABP4: a novel candidate gene for polycystic ovary syndrome.

Authors:  Jing Wang; Jingwen Tang; Binbin Wang; Junjie Song; Jingjing Liu; Zhaolian Wei; Feng Zhang; Xu Ma; Yunxia Cao
Journal:  Endocrine       Date:  2009-10-21       Impact factor: 3.633

8.  Role of the fatty acid binding protein mal1 in obesity and insulin resistance.

Authors:  Kazuhisa Maeda; K Teoman Uysal; Liza Makowski; Cem Z Görgün; Genichi Atsumi; Rex A Parker; Jens Brüning; Ann Vogel Hertzel; David A Bernlohr; Gökhan S Hotamisligil
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

9.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.

Authors:  Masato Furuhashi; Gürol Tuncman; Cem Z Görgün; Liza Makowski; Genichi Atsumi; Eric Vaillancourt; Keita Kono; Vladimir R Babaev; Sergio Fazio; MacRae F Linton; Richard Sulsky; Jeffrey A Robl; Rex A Parker; Gökhan S Hotamisligil
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

10.  Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans.

Authors:  Norbert Stefan; Konstantinos Kantartzis; Nora Celebi; Harald Staiger; Jürgen Machann; Fritz Schick; Alexander Cegan; Michaela Elcnerova; Erwin Schleicher; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Diabetes Care       Date:  2009-11-04       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.